8-K: Enzo Biochem Completes Merger, Goes Private

Enzo Biochem, Inc. has completed its merger with Bethpage Merger Sub, Inc., becoming a wholly owned subsidiary of Bethpage Parent, Inc. and delisting its common stock.

Summary

• Enzo Biochem, Inc. completed its merger with Bethpage Merger Sub, Inc. on August 20, 2025, with the Company surviving as a wholly owned subsidiary of Bethpage Parent, Inc.
• Each outstanding share of common stock was automatically converted into the right to receive $0.70 in cash, without interest and subject to applicable withholding taxes.
• Vested Company restricted stock units (RSUs) were cancelled and converted into cash equal to the product of the total number of shares underlying the RSU and the $0.70 merger consideration.
• Unvested Company RSUs and all options to purchase shares were automatically cancelled without any consideration.
• Each warrant to acquire shares was cancelled and converted into the right to receive an amount set forth in the applicable Warrant Cancellation Agreement.
• The Company's common stock ceased trading on the OTCQX tier of the OTC Markets prior to the opening of trading on August 20, 2025.
• The Company intends to file a Form 15 with the SEC to deregister its common stock and suspend its reporting obligations under the Exchange Act.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for shareholders receiving cash, but negative for those with unvested equity or who wished to remain public investors. The event itself is a completion of a pre-announced transaction, so it's largely expected.

Positives

• Shareholders received a cash consideration of $0.70 per share, providing liquidity for their investment.
• Vested restricted stock units were converted to cash, benefiting their holders.

Negatives

• Unvested restricted stock units and stock options were cancelled without consideration, potentially impacting employees or former employees.
• The company's common stock has been delisted, removing public trading access for investors.
• Shareholders no longer hold an equity interest in the company.

Future Outlook

The company will operate as a wholly owned subsidiary of Bethpage Parent, Inc. and intends to deregister its common stock with the SEC, suspending its public reporting obligations.

Management Comments

• The departure of directors was in connection with the consummation of the Merger and not as a result of any disagreement with the Company.

Industry Context

This transaction represents a company transitioning from public to private ownership, a common strategy for companies seeking to streamline operations, reduce regulatory burdens, or pursue long-term strategies away from public market scrutiny. It removes a smaller player from the publicly traded healthcare/biochem sector.

Comparison to Industry Standards

• NA. This filing details the completion of a specific merger transaction, not operational or financial results that can be benchmarked against industry peers or global standards.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash consideration for their shares, losing their equity interest and public trading access.
• Employees: Those with unvested restricted stock units or options had their equity cancelled without consideration, while those with vested RSUs received cash.
• Management: Key directors departed as part of the transition to private ownership.

Next Steps

• Filing of Form 15 with the SEC to deregister common stock.
• Suspension of reporting obligations under the Securities Exchange Act of 1934.

Key Dates

Keywords

Enzo Biochem, Merger, Acquisition, Going Private, Delisting, Biochem, Healthcare, Diagnostics, SEC Filing, Form 8-K